Cite
HARVARD Citation
Wang, H. et al. (2022). Lung adenocarcinoma with EGFR 19Del and an ALK rearrangement benefits from alectinib instead of an EGFR-TKI: A case report. Medicine. 101 (35), pp. e30316-. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Wang, H. et al. (2022). Lung adenocarcinoma with EGFR 19Del and an ALK rearrangement benefits from alectinib instead of an EGFR-TKI: A case report. Medicine. 101 (35), pp. e30316-. [Online].